Linwah Yip

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3568245/publications.pdf

Version: 2024-02-01

		66234	53109
119	7,641 citations	42	85
papers	citations	h-index	g-index
119	119	119	5271
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?. Surgery, 2022, 171, 17-22.	1.0	6
2	Chronic Lymphocytic Thyroiditis and Aggressiveness of Pediatric Differentiated Thyroid Cancer. Laryngoscope, 2022, 132, 1668-1674.	1.1	5
3	How and when is multiglandular disease diagnosed in sporadic primary hyperparathyroidism?. Surgery, 2022, 171, 35-39.	1.0	5
4	Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls. Endocrine, 2022, 76, 395-406.	1.1	2
5	Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer. Thyroid, 2022, 32, 236-244.	2.4	12
6	Changes in frailty after parathyroid and thyroid surgery. Surgery, 2022, 171, 718-724.	1.0	6
7	Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations. Endocrine-Related Cancer, 2022, 29, 467-473.	1.6	6
8	Histologic hypercellularity in a biopsied normal parathyroid gland does not correlate with hyperfunction in primary hyperparathyroidism. Surgery, 2021, 169, 524-527.	1.0	3
9	A specific enhanced recovery protocol decreases opioid use after thyroid and parathyroid surgery. Surgery, 2021, 169, 197-201.	1.0	12
10	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched caseâ€control study. Cancer, 2021, 127, 1779-1787.	2.0	38
11	Molecular alterations in Hýrthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	1.6	23
12	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3228-3238.	1.8	36
13	Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?. Thyroid, 2021, 31, 1673-1682.	2.4	19
14	Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?. Endocrine-Related Cancer, 2021, 28, 621-630.	1.6	6
15	Automatic Detection of Thyroid and Adrenal Incidentals Using Radiology Reports and Deep Learning. Journal of Surgical Research, 2021, 266, 192-200.	0.8	5
16	Reinventing Yourself Virtually: Fifth Annual Society of Asian Academic Surgeons Virtual Conference. Journal of Surgical Research, 2021, 267, 612-618.	0.8	1
17	The impact of race and ethnicity on thyroid nodules, malignancy risk, and surgical management commentary on "Comparing the rate and extent of malignancy in surgically excised thyroid nodules across race and ethnicity― American Journal of Surgery, 2021, , .	0.9	0
18	Response to the Comment on "The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults― Annals of Surgery, 2021, 274, e746-e747.	2.1	2

#	Article	IF	CITATIONS
19	A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia. Surgery, 2020, 167, 137-143.	1.0	6
20	Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism. Surgery, 2020, 167, 160-165.	1.0	26
21	BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. European Journal of Cancer, 2020, 124, 161-169.	1.3	41
22	Clinical and Biochemical Features of Pheochromocytoma Characteristic of Von Hippel–Lindau Syndrome. World Journal of Surgery, 2020, 44, 570-577.	0.8	12
23	MON-LB79 Do Ultrasound Patterns and Clinical Parameters Modify the Probability of Thyroid Cancer Predicted by Molecular Testing in Thyroid Nodules With Indeterminate Cytology?. Journal of the Endocrine Society, 2020, 4, .	0.1	0
24	The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Annals of Surgery, 2020, 272, 621-627.	2.1	23
25	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. Scientific Reports, 2020, 10, 8031.	1.6	12
26	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, e21-e93.	2.1	290
27	Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, 399-410.	2.1	33
28	Thoughtful Utilization of Molecular Testing in Refining Thyroid Nodule Risk Assessment: Do Not Throw Out the Baby. Thyroid, 2020, 30, 474-475.	2.4	3
29	Novel Findings on SPECT-CT Tc-99 Sestamibi Imaging for Primary Hyperparathyroidism. Journal of Surgical Research, 2020, 252, 216-221.	0.8	3
30	OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations. Journal of the Endocrine Society, 2020, 4, .	0.1	2
31	Remembering the Hippocratic Oath in Surgical Training. JAMA Surgery, 2019, 154, 958.	2.2	0
32	Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules: A Cost-Effectiveness Analysis. Thyroid, 2019, 29, 1237-1243.	2.4	61
33	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. Thyroid, 2019, 29, 1279-1285.	2.4	7
34	Completion thyroidectomy: A risky undertaking?. American Journal of Surgery, 2019, 218, 695-699.	0.9	26
35	Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. Thyroid, 2019, 29, 252-257.	2.4	4
36	Comparison of the collection approaches of 2 large thyroid fine-needle aspiration practices reveals differing advantages for cytology and molecular testing adequacy rates. Journal of the American Society of Cytopathology, 2019, 8, 243-249.	0.2	4

#	Article	IF	Citations
37	Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing. Surgical Clinics of North America, 2019, 99, 587-598.	0.5	11
38	Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathology, 2019, 127, 161-168.	1.4	50
39	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	3.4	317
40	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid, 2019, 29, 161-173.	2.4	69
41	Outcomes of Adrenal Venous Sampling in Patients with Bilateral Adrenal Masses and ACTHâ€Independent Cushing's Syndrome. World Journal of Surgery, 2019, 43, 527-533.	0.8	26
42	Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-Related Cancer, 2019, 26, 803-814.	1.6	38
43	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Nextâ€Generation Molecular Testing. World Journal of Surgery, 2018, 42, 2840-2845.	0.8	2
44	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer, 2018, 124, 1682-1690.	2.0	274
45	Retropharyngeal Parathyroid Glands: Important Differences. World Journal of Surgery, 2018, 42, 437-443.	0.8	8
46	Sestamibi SPECT/CT versus SPECT only for preoperative localization in primary hyperparathyroidism: a single institution 8-year analysis. Surgery, 2018, 163, 643-647.	1.0	21
47	Expanding the Options for Patient-Guided Decision Making in Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2018, 319, 76.	3.8	0
48	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. Journal of the National Cancer Institute, 2018, 110, 362-370.	3.0	60
49	Mountain Climbing, Motherhood, and Surgical Practice. JAMA Surgery, 2018, 153, 652.	2.2	2
50	An Evolving Understanding of the Clinical Implications of NIFTP. World Journal of Surgery, 2018, 42, 327-328.	0.8	1
51	Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery, 2018, 163, 81-87.	1.0	46
52	Patient Age–Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 438-445.	0.8	102
53	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 2787-2795.	0.8	58
54	Gasless Transaxillary Endoscopic Thyroidectomy with Robotic Assistance: A High-Volume Experience in North America. Thyroid, 2018, 28, 1655-1661.	2.4	20

#	Article	IF	CITATIONS
55	3D Anatomic Adrenal Modeling Aids Preoperative Planning in Cortical-Sparing Adrenalectomy. VideoEndocrinology, 2018, 5, .	0.1	0
56	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3241-3250.	1.8	80
57	Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 2017, 24, 3624-3630.	0.7	24
58	Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery, 2017, 161, 168-175.	1.0	56
59	Does impotence improve afterÂparathyroidectomy in men withÂprimary hyperparathyroidism?. Surgery, 2016, 159, 204-210.	1.0	4
60	Molecular-Directed Treatment of Differentiated Thyroid Cancer. JAMA Surgery, 2016, 151, 663.	2.2	35
61	Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements. Endocrine Pathology, 2016, 27, 147-152.	5.2	8
62	Comparative characteristics of primary hyperparathyroidism in pediatric and young adult patients. Surgery, 2016, 160, 1008-1016.	1.0	15
63	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
64	Intraoperative Parathyroid Hormone Aspiration: Implementation and Technique. VideoEndocrinology, 2016, 3, .	0.1	4
65	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. Annals of Surgery, 2015, 262, 519-525.	2.1	100
66	Riskâ€Directed Algorithms for Pediatric PTC Patients: Is It Time?. World Journal of Surgery, 2015, 39, 2266-2268.	0.8	1
67	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	2.4	344
68	Systematic screening after <scp>C</scp> hernobyl: Insights on radiationâ€induced thyroid cancer. Cancer, 2015, 121, 339-340.	2.0	2
69	The clinical importance of parathyroid atypia: Is long-term surveillance necessary?. Surgery, 2015, 158, 929-936.	1.0	28
70	Nonoperative Management of Bilateral Adrenal Incidentalomas. JAMA Surgery, 2015, 150, 978.	2.2	0
71	Adrenal Imaging Features Predict Malignancy Better than Tumor Size. Annals of Surgical Oncology, 2015, 22, 721-727.	0.7	9
72	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448

#	Article	IF	CITATIONS
73	Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. Journal of Surgical Oncology, 2015, 111, 43-50.	0.8	30
74	Molecular diagnostic testing and the indeterminate thyroid nodule. Current Opinion in Oncology, 2014, 26, 8-13.	1.1	21
75	Use of Molecular Markers for Cytologically Indeterminate Thyroid Nodules to Optimize Surgical Management. Current Surgery Reports, 2014, 2, 1.	0.4	2
76	The Final Intraoperative Parathyroid Hormone Level: How Low Should It Go?. World Journal of Surgery, 2014, 38, 558-563.	0.8	46
77	Thyroid Nodules (≥4Âcm): Can Ultrasound and Cytology Reliably Exclude Cancer?. World Journal of Surgery, 2014, 38, 614-621.	0.8	105
78	The Small Abnormal Parathyroid Gland is Increasingly Common and Heralds Operative Complexity. World Journal of Surgery, 2014, 38, 1274-1281.	0.8	49
79	Molecular Testing of Thyroid Nodules: Distinguishing Misuse from Appropriate Use. Annals of Surgical Oncology, 2014, 21, 1768-1769.	0.7	1
80	Thyroid Nodules ≥4Âcm: Can Ultrasound and Cytology Reliably Exclude Cancer? Reply. World Journal of Surgery, 2014, 38, 1556-1557.	0.8	46
81	Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. Surgery, 2014, 156, 1453-1460.	1.0	47
82	Fibromyalgia symptoms and medication requirements respond toÂparathyroidectomy. Surgery, 2014, 156, 1614-1621.	1.0	10
83	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	2.0	445
84	Thyroid nodules with <i>KRAS</i> mutations are different from nodules with <i>NRAS</i> and <i>HRAS</i> mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology, 2014, 122, 873-882.	1.4	63
85	Clinical Application of Molecular Testing of Fine-needle Aspiration Specimens in Thyroid Nodules. Otolaryngologic Clinics of North America, 2014, 47, 557-571.	0.5	15
86	<i>PAX8/PPARγ</i> Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. Thyroid, 2014, 24, 1369-1374.	2.4	83
87	A novel mutation in the succinate dehydrogenase subunit D gene in siblings with the hereditary paraganglioma–pheochromocytoma syndrome. SAGE Open Medical Case Reports, 2014, 2, 2050313X1455352.	0.2	0
88	A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy. Annals of Surgery, 2014, 260, 163-168.	2.1	66
89	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	3.8	775
90	Outcome and Prognostic Factors After Adrenalectomy for Patients with Distant Adrenal Metastasis. Annals of Surgical Oncology, 2013, 20, 3491-3496.	0.7	59

#	Article	IF	CITATIONS
91	BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer. Annals of Surgical Oncology, 2013, 20, 47-52.	0.7	121
92	Thyroid nodule evaluation: How much is too much?. Surgery, 2013, 154, 1417-1419.	1.0	1
93	Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery, 2013, 154, 730-738.	1.0	34
94	New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers. Clinical Cancer Research, 2013, 19, 2283-2288.	3.2	84
95	<i>RAS</i> Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E914-E922.	1.8	128
96	<i>BRAF</i> mutation detection in indeterminate thyroid cytology specimens. Cancer Cytopathology, 2013, 121, 197-205.	1.4	71
97	Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1586-1591.	2.1	46
98	"Colloidâ€Rich†follicular neoplasm/suspicious for follicular neoplasm thyroid fineâ€needle aspiration specimens: Cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology, 2013, 121, 718-728.	1.4	20
99	RAS Mutations in Thyroid Cancer. Oncologist, 2013, 18, 926-932.	1.9	144
100	Suspicious Ultrasound Characteristics Predict <i>BRAF</i> Sup>V600E-Positive Papillary Thyroid Carcinoma. Thyroid, 2012, 22, 585-589.	2.4	48
101	Cost Impact of Molecular Testing for Indeterminate Thyroid Nodule Fine-Needle Aspiration Biopsies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1905-1912.	1.8	131
102	Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. Journal of the American College of Surgeons, 2012, 215, 546-554.	0.2	18
103	Immediate laparoscopic adrenalectomy versus observation: cost evaluation for incidental adrenal lesions with atypical imaging characteristics. American Journal of Surgery, 2012, 204, 462-467.	0.9	8
104	Predicting malignancy in thyroid nodules: Molecular advances. Head and Neck, 2012, 34, 1355-1361.	0.9	5
105	A combined molecularâ€pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer, 2012, 118, 2069-2077.	2.0	139
106	Thyroid Carcinoma: The Surgeon's Perspective. Radiologic Clinics of North America, 2011, 49, 463-471.	0.9	9
107	MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2011, 18, 2035-2041.	0.7	216
108	Both BRAF V600E Mutation and Older Age (≥65ÂYears) are Associated with Recurrent Papillary Thyroid Cancer. Annals of Surgical Oncology, 2011, 18, 3566-3571.	0.7	59

#	Article	IF	CITATIONS
109	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3390-3397.	1.8	712
110	The Adrenal Mass: Correlation of Histopathology with Imaging. Annals of Surgical Oncology, 2010, 17, 846-852.	0.7	48
111	Summary statement: Utility of molecular marker testing in thyroid cancer. Surgery, 2010, 148, 1313-1315.	1.0	25
112	Contribution of molecular testing to thyroid fineâ€needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significanceâ€. Cancer Cytopathology, 2010, 118, 17-23.	1.4	229
113	The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer. Oncologist, 2010, 15, 1285-1293.	1.9	58
114	Differentiated Thyroid Cancers of Follicular Cell Origin. Cancer Treatment and Research, 2010, 153, 35-56.	0.2	1
115	Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 2009, 146, 1215-1223.	1.0	149
116	Sestamibi SPECT Intensity Scoring System in Sporadic Primary Hyperparathyroidism. World Journal of Surgery, 2009, 33, 426-433.	0.8	19
117	Can a Lightbulb Sestamibi SPECT Accurately Predict Singleâ€Gland Disease in Sporadic Primary Hyperparathyroidism?. World Journal of Surgery, 2008, 32, 784-792.	0.8	27
118	Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery, 2008, 144, 1002-1007.	1.0	30
119	Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma. Surgery, 2008, 144, 949-955.	1.0	16